Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Vivos Therapeutics, Inc.

NASDAQ: VVOS · Industrial Applications and Services · 6 alerts · CIK 1716166

Share price
$0.0822Close, Nov 16
Market cap
$1.14M
Shares outstanding
13.89MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Vivos Therapeutics, Inc. filings on SEC EDGAR ↗

7:00 AM ET 8-K
Nasdaq/NYSE Compliance Notice

Vivos Therapeutics Nasdaq/NYSE Compliance Notice

Vivos Therapeutics received a letter from Nasdaq confirming that the company has regained compliance with the minimum stockholders' equity requirement of $2.5 million under Listing Rule 5550(b)(1). The compliance was achieved following a transaction involving the issuance of Series C Convertible Preferred Stock, which is expected to increase stockholders' equity by more than $10 million. The company must continue to evidence compliance in its next periodic report to avoid potential delisting.

Counterparty
The Nasdaq Stock Market LLC
4:50 PM ET 8-K
M&A Deal

Vivos Therapeutics Signs $12M M&A Deal with SOD Sciences, Inc.

Vivos Therapeutics completed the acquisition of an 11% equity stake in SOD Sciences and a 50% co-ownership interest in SOD's pseudohypoxia early-warning test. The transaction was valued at $12 million, paid via the issuance of 12,000 shares of Series C Convertible Preferred Stock, and is expected to add over $10 million to Vivos' stockholders' equity.

Value
$12M
Counterparty
SOD Sciences, Inc.

“Today Vivos became more than a healthcare company just treating sleep apnea. We expect this transaction to add more than $10 million to our stockholders’ equity, and we now own half of a test designed to identify patients whose sleep apnea may be contributing to chronic disease.”

R. Kirk Huntsman, Chairman and Chief Executive Officer of Vivos
8:46 AM ET 8-K
M&A Deal

Vivos Therapeutics Signs $12M M&A Deal with SOD Sciences, Inc.

Vivos Therapeutics entered into a definitive agreement to acquire an 11% equity stake in SOD Sciences and a 50% co-ownership interest in a proprietary pseudohypoxia early-warning test. The transaction is valued at $12 million, paid via the issuance of 12,000 shares of newly created Series C Convertible Preferred Stock, and is intended to bolster stockholders' equity for Nasdaq compliance.

Value
$12M
Counterparty
SOD Sciences, Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.